An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia
Shiina A, Kanahara N, Sasaki T, Oda Y, Hashimoto T, Hasegawa T, Yoshida T, Iyo M, Hashimoto K
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 90 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
- Intake measured by
- Not stated
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2015-04-23 · Clin Psychopharmacol Neurosci · vol. 13 · issue 1 · pp. 62–67
- Cited
- 108 citations · more than 94% of similar papers · 3.7× the field average
- Impact
- Top 10% most cited in its field
- References
- 66 works
- Access
- Open access (free to publish) · CC-BY-NC
- Research areas
- Genomics, phytochemicals, and oxidative stress · Tryptophan and brain disorders · Calcium signaling and nucleotide metabolism
- Keywords
- Sulforaphane, Schizophrenia (object-oriented programming), Internal medicine, Cognition, Medicine, Positive and Negative Syndrome Scale, Clinical trial, Oxidative stress, Cognitive impairment, Psychiatry, Psychology, Psychosis
9 authors
From JP
- Akihiro Shiina · correspondingChiba University Hospital; Center for Forensic Mental Health, Chiba University
- Nobuhisa KanaharaCenter for Forensic Mental Health, Chiba University
- Tsuyoshi Goto SasakiChiba University Hospital
- Yasunori OdaChiba University
- Tasuku HashimotoChiba University
- Tadashi HasegawaChiba University Hospital
Abstract
Objective
Schizophrenia is a mental disorder characterized by severe cognitive impairment. Accumulating evidence suggests a role for oxidative stress in the pathophysiology of schizophrenia. Sulforaphane (SFN) extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. In this study, we attempted to evaluate the effect of SFN on cognitive impairment in medicated patients with schizophrenia.
Methods
We recruited a total of 10 outpatients with schizophrenia, all of whom gave informed consent. Participants took 3 tablets of SFN, consisting of 30 mg of SFN-glucosinolate per day, for 8 weeks. Clinical symptoms using the Positive and Negative Syndrome Scale (PANSS) and cognitive function using the Japanese version of CogState battery were evaluated at the beginning of the study and at week 8.
Results
A total of 7 patients completed the trial. The mean score in the Accuracy component of the One Card Learning Task increased significantly after the trial. However, we detected no other significant changes in participants.
Conclusions
This result suggests that SFN has the potential to improve cognitive function in patients with schizophrenia.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.